8-K
filed June 20, 2023, 7:59 PM ET
ticker CTMX
CIK 0001501989
other
confidence high
sentiment neutral
materiality 0.15
CytomX Therapeutics stockholders elect directors, ratify auditor, approve say-on-pay at 2023 Annual Meeting
CytomX Therapeutics, Inc.
- Matthew P. Young re-elected to board with 23.8M votes for (0.7M against); Elaine V. Jones re-elected with 18.4M for (6.1M against).
- Ratification of Ernst & Young as independent auditor for FY2023 passed with 43.3M for, 0.6M against.
- Non-binding advisory vote on executive compensation approved with 22.1M for, 1.5M against, 0.9M abstain, and 19.3M broker non-votes.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CytomX Therapeutics, Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
Proposal 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. FOR AGAINST ABSTAIN 43,291,956 562,880 57,844 As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CytomX Therapeutics, Inc. shareholders approved Election of Class II directors at the 2023-06-14 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
Proposal 1. The Company’s stockholders elected the Class II director nominees below to the Company’s Board of Directors to hold office until the 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or the earlier of their death, resignation or removal. NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Matthew P. Young 23,793,074 732,946 38,185 19,348,478 Elaine V. Jones, Ph.D. 18,414,845 6,111,386 37,974 19,348,478
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CytomX Therapeutics, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-06-14 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
Proposal 3. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 22,139,070 1,486,286 938,849 19,348,475
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.